jeudi 20 juin 2019

Onco Actu du 20 juin 2019


2.10 ETIOLOGIE - ALCOOL



Many women unaware of the link between alcohol and breast cancer [NHS Choices]










2.5 ETIOLOGIE - GÈNES



Diverse Population GWAS Delivers Distinct Disease, Trait Associations [Genome Web]











Lack of diversity in genetic research is risky [Fred Hutch]










3. PRÉVENTION



Looking to the future of breast cancer prevention [PHG Foundation]











3.1.1 PRÉVENTION - TABAC - E-CIGS



AACR Takes Action Against the “Epidemic” of Youth E-cigarette Use [Cancer Research Catalyst]










E-Cigarette Exploded in a Teenager’s Mouth, Damaging His Jaw [NY Times]











4.5 DÉP., DIAG. & PRONO. - COLORECTAL



Sedation Method Does Not Affect Colonoscopy Detection Rate [University of Missouri]











5. TRAITEMENTS



Game-changing cancer drugs which can attack all tumours will be fast-tracked by NHS [The Telegraph]











NHS to ‘fast track’ new personalised cancer medicines – but it’s not ready quite yet [Cancer Research UK]










5.1 TRAITEMENTS - PRÉ-CLINIQUE



Ro Versus Musashi: How One Molecule Can Turn Cancer Cells Back to Normal [Memorial Sloan Kettering Cancer Center]











An Ounce of Prevention: Preoperative Management of Inflammation May Stave Off Cancer Recurrences [Beth Israel Deaconess Medical Center]










Human-on-a-chip Model Enables Simultaneous Testing of Cancer Drug Efficacy and Off-Target Toxicity to Enable Determination of Therapeutic Index [Hesperos]











5.12.10 IMMUNOTHÉRAPIES - FUSIONS ET ACQUISITIONS



Investor day prep at Merck includes a new strategy to pick up the pace on M&A — report [EndPoints]











5.12.3 IMMUNOTHÉRAPIES-COMBINAISONS



Oncolytics Bio Tacks On Cancer Combo Study with Merck KGaA, Pfizer [Xconomy]











5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



A new number 1 drug? Keytruda tapped to top the 10 biggest blockbusters on the world stage by 2024 [EndPoints]











5.2 PHARMA



Kymera rolls out new animal data on its lead protein-degradation drug to treat lymphoma [Fierce Biotech]











Regorafenib to be tested in brain cancer patients in multi-arm cooperation trial [Bayer]











Sanofi's John Reed continues to reorganize R&D, cutting 466 jobs while boosting cancer, gene therapy research [EndPoints]











5.2.1 PHARMA - PARTENARIATS



Gilead taps Nurix's protein degradation tech in $45M cancer pact [Fierce Biotech]











With $45M Nurix Deal, Gilead Enters Crowded Protein Degradation Field [Xconomy]











Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases [Gilead]











Gilead baits new alliance with $45M upfront, diving into the busy protein degradation field [EndPoints]











5.2.3 PHARMA - ÉCONOMIE



Distrust is frustrating U.K. NHS-industry cooperation: report [Fierce Biotech]











New study questions the need for 12 years of market exclusivity for biologics [EndPoints]











5.4 TRAITEMENTS - ECONOMIE



Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity [NICE]











NICE U-turn opens up new treatment option for some adults with leukaemia [Cancer Research UK]











5.5.3 ASCO (PROSTATE)



More Treatment Options Emerging for Some Men with Metastatic Prostate Cancer [NCI]











6.10.1 POLITIQUES (USA)



Biden wants to cure cancer. Now Trump does, too. But cancer, like health care, is complicated [STAT]










6.6 PUBLICATIONS



Unravelling the mysteries of preprints and peer review [Nature]











6.7.1 IA/BIOINFORMATIQUE



What if AI in health care is the next asbestos? [STAT]